Company Overview - FibroGen, Inc. is a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia [3] - Roxadustat (爱瑞卓®, EVRENZO™) is approved in Europe, Japan, and other countries for treating anemia in chronic kidney disease (CKD) patients, both on and not on dialysis [3] - The company is evaluating a Phase 3 trial for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. [3] - FG-3246 (FOR46), a first-in-class antibody-drug conjugate targeting CD46, is in Phase 2 development for metastatic castration-resistant prostate cancer [3] - The development program also includes FG-3180, a CD46-targeted PET biomarker [3] Upcoming Events - FibroGen will present at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, in New York [1] - CEO Thane Wettig will participate in a panel discussing potential stock-moving catalysts for rare disease companies [1] - The management team will be available for one-on-one meetings during the conference for interested investors [2]